Clinical Trials on Neisseria Meningitides Meningitis

Total 458 results

Walvax Biotechnology Co., Ltd.

Completed

A Study to Demonstrate Non-inferior Immunogenicity of Yuxi Walvax MPV ACYW® Vaccine in Healthy Subjects Aged 2-10 Years

Neisseria Meningitides Meningitis

Mali
Pfizer

Completed

NeisVac-C Single Prime Study in Infants

Neisseria Meningitidis

Poland, Spain
Public Health England

Completed

Immunogenicity and Reactogenicity of a Meningococcal B Outer Membrane Vesicle Vaccine Given in a 0,6,12 Month Schedule to Health UK Adults

Neisseria Meningitidis
University of Oxford

Completed

Investigating Meningococcal Vaccines in Adults

Meningococcal Infections | Neisseria Meningitidis | Meningococcal Vaccines | Factor H-binding Protein, Neisseria Meningitidi

United Kingdom
Pfizer

Completed

Safety and Immunogenicity Study of MenC-TT Vaccine (NeisVac-C) in Toddlers Previously Immunized With PCV7 (Prevenar®)

Neisseria Meningitidis (Bacterial Meningitis) | Invasive Pneumococcal Disease (IPD)

Germany
University Hospital, Rouen
Institut Pasteur; Direction Générale de la Santé, France

Completed

Evaluation of Immune Response Against the Strain of Neisseria Meningitidis B: 14, P1-7, 16 in Patients Having to be Vaccinated MenBVac® (Extension EFFIVAC) (Exten Effivac)

Neisseria Meningitidis

France
Public Health England

Completed

Meningococcal B Vaccination in University Students (MNB3)

Neisseria Meningitidis Serogroup B

United Kingdom
Sanofi Pasteur, a Sanofi Company

Completed

Dose Comparison Study of Menactra® in US Children

Meningitis | Meningococcal Infection | Neisseria Meningitidis

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of Reduced Dose of Menomune® in Children Who Previously Received Meningococcal Diphtheria Toxoid Conjugate Vaccine

Meningitis | Neisseria Meningitidis | Meningococcemia

United States
University of Adelaide

Completed

Study to Assess Oropharyngeal Carriage of N. Meningitidis in South Australian School Leavers (B Part Of It)

Neisseria Meningitidis

Australia
Pfizer

Completed

A Trial to Assess the Safety, Tolerability and Immunogenicity of Repevax and rLP2086 Vaccine When Given Together in Healthy Subjects Aged >=11 to <19 Years.

Meningitis | Meningococcal Vaccine | rLP2086 | Repevax | N Meningitidis Serogroup B

Germany, Finland, Poland
University Hospital, Montpellier

Unknown

Evaluation of Post Infectious Inflammatory Reaction (PIIR) Concerning Children After Streptococcus Pneumoniae, Streptococcus Pyogenes and Neisseria Meningococcus Invasive Infection (RIPI)

Streptococcus Pyogenes Infection | Streptococcus Pneumonia | Neisseria Meningitides Meningitis

France
University of Adelaide

Completed

The Long-term Impact of Invasive Meningococcal Disease in Australian Adolescents and Young Adults (AMEND)

Meningococcal Infections | Neisseria Infection | Neisseria Meningitis Sepsis

Australia
University of Southampton
University Hospital Southampton NHS Foundation Trust

Completed

Challenge of the Nasopharynx With Neisseria Lactamica Expressing the Meningococcal Protein Neisseria Adhesin A (NadA) (NadA-Lac4)

Meningitis, Bacterial | Neisseria Infection

United Kingdom
GlaxoSmithKline

Completed

Immunogenicity, Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Hib-MenCY-TT (MenHibrix®) Vaccine Compared to Merck & Co, Inc. PedvaxHIB Vaccine in Healthy Infants and Toddlers 12 to 15 Months of Age

Neisseria Meningitidis | Haemophilus Influenzae Type b

United States
GlaxoSmithKline

Completed

Study in Toddlers to Demonstrate Non-inferiority of GSK Biologicals' Hib-MenC & to Evaluate Persistence up to 5 Years.

Neisseria Meningitidis | Haemophilus Influenzae Type b

Australia
GlaxoSmithKline

Completed

Comparison of GSKBiologicals' Hib-MenCY-TT Vaccine vs Licensed Hib Conjugate or Meningococcal Vaccine

Neisseria Meningitidis | Haemophilus Influenzae Type b

United States
GlaxoSmithKline

Completed

Long-Term Antibody Persistence at 1, 3 and 5 Years After a Fourth Dose of GSK Biologicals' Hib-MenCY-TT Vaccine Compared to ActHIB

Neisseria Meningitidis | Haemophilus Influenzae Type b

United States
GlaxoSmithKline

Completed

Long-term Persistence Study to Assess a Booster Dose of GSK Biologicals' Hib-MenC

Neisseria Meningitidis | Haemophilus Influenzae Type b

Spain
GlaxoSmithKline

Completed

Primary & Booster Study in Infants to Demonstrate Non-inferiority, Persistence & Immunogenicity of Hib-MenC Vaccine

Neisseria Meningitidis | Haemophilus Influenzae Type b

Finland, Italy
GlaxoSmithKline

Completed

Primary & Booster Immunogenicity Study of GSK Biologicals' Hib-MenC Versus a Licensed Men-C Vaccine

Neisseria Meningitidis | Haemophilus Influenzae Type b

Poland, United Kingdom
GlaxoSmithKline

Completed

Study of a Booster Dose of Hib-MenC Conjugate Vaccine vs Infanrix Hexa When Given to 14 Month Old Subjects

Neisseria Meningitidis | Haemophilus Influenzae Type b

Spain
MCM Vaccines B.V.
Merck Sharp & Dohme LLC; Sanofi Pasteur, a Sanofi Company

Completed

Spanish Mixed HEXA/PENTA/HEXA Schedule (V419-010)

Virus Diseases | Bacterial Infections | Neisseria Meningitidis
GlaxoSmithKline

Completed

Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 12 to 15 Months of Age.

Neisseria Meningitidis | Haemophilus Influenzae Type b

United States, Mexico
GlaxoSmithKline

Completed

Hib-MenCY-TT Vaccine Study Compared to Licensed Hib and Meningococcal Serogroup C Conjugate Vaccines

Neisseria Meningitidis | Haemophilus Influenzae Type b

Australia
GlaxoSmithKline

Completed

Study to Evaluate GSK Biologicals' GSK2197870A Vaccine Given as Primary Course in Infants

Neisseria Meningitidis | Haemophilus Influenzae Type b

United Kingdom
GlaxoSmithKline

Completed

Persistence of Antibodies at 3, 4 and 6 Years of Age After Vaccination With Meningococcal, Pneumococcal and Hib Vaccines

Neisseria Meningitidis | Haemophilus Influenzae Type b

Spain, Germany, Poland
Sanofi Pasteur, a Sanofi Company

Completed

Concomitant Administration of a New Hexavalent Vaccine With a Meningococcal Serogroup C Conjugate Vaccine in Healthy Infants During Primary Series Immunisation Followed by Booster Vaccination

Virus Diseases | Bacterial Infections | Neisseria Meningitidis

Finland
GlaxoSmithKline

Completed

Safety, Reactogenicity & Immunogenicity Study to Evaluate a Booster Dose of GSK Biologicals' Hib-MenC Given With Priorix™ in Toddlers (13-14 m) Primed With 3 Doses of Hib and MenC-CRM197

Neisseria Meningitidis | Haemophilus Influenzae Type b

Spain
Prof. Elizabeth Miller
Novartis Vaccines

Completed

Study of Meningococcal B Vaccine and ACWY Conjugate Vaccine in Healthy Adults (MenOccy)

Meningococcal Meningitis, Serogroup A | Meningococcal Meningitis, Serogroup B | Meningococcal Meningitis, Serogroup C | Meningococcal Meningitis, Serogroup Y | Meningococcal Meningitis, Serogroup W

United Kingdom
University Hospital, Strasbourg, France

Completed

Causes and Management of Aseptic Meningitis : A Retrospective Cohort Study in Strasbourg University Hospital (Meningitis)

Aseptic Meningitis

France
GlaxoSmithKline

Completed

Study of Long-term Antibody Persistence After a Booster Dose of Menitorix Vaccine

Neisseria Meningitidis | Haemophilus Influenzae Type b | Neisseria Meningitidis-Haemophilus Influenzae Type b Vaccine

Poland, United Kingdom
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of Menactra® Vaccine in Adolescents in Saudi Arabia

Meningococcal Infections | Neisseria Meningitidis

Saudi Arabia
GlaxoSmithKline

Completed

Primary & Booster Study to Evaluate the Immunogenicity and Safety of Menitorix Vaccine in Preterm Infants

Neisseria Meningitidis | Haemophilus Influenzae Type b

Spain
GlaxoSmithKline

Completed

WEUSKOP6166: Lamotrigine and Aseptic Meningitis

Epilepsy
University Medical Centre Ljubljana
Harvard University; University of Ljubljana School of Medicine, Slovenia; Slovenian...

Unknown

Aseptic Meningoencephalitis in Slovenia

Aseptic Meningitis

Slovenia
MCM Vaccines B.V.

Completed

Immunogenicity and Safety of V419 (PR51) in Combination With MCC in Infants and Toddlers (V419-011)

Virus Diseases | Bacterial Infections | Neisseria Meningitidis
University of Minnesota
National Institute of Neurological Disorders and Stroke (NINDS); Medical Research... and other collaborators

Completed

Adjunctive Sertraline for the Treatment of HIV-Associated Cryptococcal Meningitis (ASTRO-CM)

Cryptococcal Meningitis | Fungal Meningitis

Uganda
Rambam Health Care Campus

Withdrawn

Amikacin Penetration Into the Cerebrospinal Fluid

Gram Negative Meningitis | Post Traumatic Bacterial Meningitis

Israel
Assiut University

Unknown

Role of CSF-CRPand Serum Procalcitonin in Differentiation Between Bacterial and Viral Meningitis in Children

Meningitis in Children
Charite University, Berlin, Germany

Recruiting

Early Diagnosis of Native and Device-associated Meningitis

Bacterial Meningitis | Implant Infection | Fungal Meningitis

Germany
Brigham and Women's Hospital

Active, not recruiting

Immunogenicity of Quadrivalent Meningococcal Conjugate Vaccine in Frequent Platelets Donors (PLAT)

Preventive Immunization; Meningitis

United States
Matinas BioPharma Nanotechnologies, Inc.
University of Minnesota

Not yet recruiting

Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial 3 (EnACT3)

Cryptococcal Meningitis
Makerere University
Gilead Sciences; University of Minnesota

Recruiting

Single Dose Liposomal Amphotericin for Asymptomatic Cryptococcal Antigenemia (ACACIA)

Cryptococcal Meningitis

Uganda
Matinas BioPharma Nanotechnologies, Inc.
University of Minnesota

Completed

Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial (EnACT) (EnACT)

Cryptococcal Meningitis

Uganda
TTY Biopharm

Unknown

Liposomal Amphotericin B for the Treatment of Cryptococcal Meningitis

Cryptococcal Meningitis

Taiwan
Novartis Pharmaceuticals

Terminated

Efficacy and Safety of Mycograb as Adjunctive Therapy for Cryptococcal Meningitis in Patients With AIDS

Cryptococcal Meningitis

South Africa
Novartis Pharmaceuticals

Terminated

Efficacy and Safety of Mycograb as Adjunctive Therapy for Cryptococcal Meningitis in Patients With AIDS

Cryptococcal Meningitis

United States
ANRS, Emerging Infectious Diseases
St George's, University of London; Yaounde Central Hospital

Unknown

Pre-Antiretroviral Therapy (ART) Cryptococcal Antigen Screening in AIDS (PreCASA)

Cryptococcal Meningitis

Cameroon
Zekai Tahir Burak Women's Health Research and Education...

Unknown

Epidemiology, Treatment and Prognosis of Neonatal Meningitis in Turkey: A Multicenter Study (NEO-MENINGITIS)

Neonatal Meningitis

Turkey

Clinical Trials on Neisseria Meningitides Meningitis

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mozambique

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations